• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    May 20, 2022 - FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

    5/20/22 3:11:09 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REGN alert in real time by email
    For Immediate Release:
    May 20, 2022

    Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE.

    “As researchers and clinicians have gained knowledge about eosinophilic esophagitis in recent years, more cases of the disorder have been recognized and diagnosed in the U.S.,” said Jessica Lee, M.D., director of the Division of Gastroenterology in the FDA’s Center for Drug Evaluation and Research. “Today’s approval will fulfill an important unmet need for the increasing number of patients with eosinophilic esophagitis.”

    EoE is a chronic inflammatory disorder in which eosinophils, a type of white blood cell, are found in the tissue of the esophagus. In adults and adolescent patients with EoE, common symptoms include difficulty swallowing, difficulty eating, and food getting stuck in the esophagus. Dupixent is a monoclonal antibody that acts to inhibit part of the inflammatory pathway. 

    The efficacy and safety of Dupixent in EoE was studied in a randomized, double-blind, parallel-group, multicenter, placebo-controlled trial, that included two 24-week treatment periods (Part A and Part B) that were conducted independently in separate groups of patients. In Part A and Part B, patients received either placebo or 300 milligrams of Dupixent every week. The two primary measurements of efficacy were the proportion of patients who achieved a certain level of reduced eosinophils in the esophagus at week 24, as determined by assessing patients’ esophageal tissue under a microscope, and the change in the patient-reported Dysphagia Symptom Questionnaire (DSQ) score from baseline to week 24. The DSQ is a questionnaire designed to measure difficulty swallowing associated with EoE, with total scores ranging from 0 to 84; higher DSQ scores indicate worse symptoms. 

    In Part A of the trial, 60% of the 42 patients who received Dupixent achieved the pre-determined level of reduced eosinophils in the esophagus compared to 5% of the 39 patients who received a placebo. Patients in Part A who received Dupixent experienced an average improvement of 22 points in their DSQ score compared to 10 points in patients who received placebo. In Part B, 59% of the 80 patients who received Dupixent achieved the pre-determined level of reduced eosinophils in the esophagus compared to 6% of the 79 patients who received a placebo. Patients in Part B who received Dupixent experienced an average improvement of 24 points in their DSQ score compared to 14 points in patients who received placebo. Assessments incorporating the perspectives from patients with EoE supported that the DSQ score improvement in patients who received Dupixent in the clinical trial was representative of clinically meaningful improvement in dysphagia. 

    The most common side effects associated with Dupixent include injection site reactions, upper respiratory tract infections, joint pain, and herpes viral infections.

    Dupixent is contraindicated in patients with known hypersensitivity to dupilumab or any of its inactive ingredients. Dupixent carries warnings and precautions, including ones addressing potential development of allergic reactions, conjunctivitis, keratitis, or joint pain; use in patients with certain parasitic infections; and use in conjunction with live vaccinations. 

    Dupixent received priority review and breakthrough therapy designations for this indication. 

    Dupixent was originally approved in 2017. It is approved for the treatment of moderate-to-severe atopic dermatitis in adult and pediatric patients aged 6 and older whose disease is not adequately controlled by topical prescription therapies or when those therapies are not advisable. Dupixent is also approved as an add-on maintenance treatment of adults and pediatric patients aged 6 and older with certain types of moderate-to-severe asthma, as well as an add-on maintenance treatment in adults with inadequately controlled chronic rhinosinusitis with nasal polyposis. 

    The FDA granted the approval of Dupixent to Regeneron Pharmaceuticals, Inc. 
     

    Related Information

    Related Information
    • NIH: Eosinophilic Esophagitis

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.


    Inquiries

    Media:
    Chanapa Tantibanchachai
    202-384-2219
    Consumer:
    888-INFO-FDA

    Get the next $REGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $REGN

    DatePrice TargetRatingAnalyst
    4/22/2025$695.00Overweight
    Cantor Fitzgerald
    2/5/2025$762.00 → $834.00Market Perform → Outperform
    Leerink Partners
    1/16/2025$1130.00 → $738.00Buy → Neutral
    UBS
    12/10/2024$565.00Underperform
    BofA Securities
    11/15/2024$1150.00Outperform
    Wolfe Research
    11/14/2024$895.00Neutral
    Citigroup
    9/24/2024$1175.00 → $1077.00Outperform → Market Perform
    Leerink Partners
    3/12/2024$1125.00Outperform
    Bernstein
    More analyst ratings

    $REGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

      SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

      2/13/24 5:12:22 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

      SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

      2/9/24 6:19:03 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

      SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

      2/9/24 9:49:31 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Schenkein David P was granted 166 shares, increasing direct ownership by 59% to 448 units (SEC Form 4)

      4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

      1/6/25 5:42:19 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Thompson Craig B. was granted 166 shares, increasing direct ownership by 37% to 620 units (SEC Form 4)

      4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

      1/6/25 4:13:03 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Coles N Anthony was granted 166 shares, increasing direct ownership by 12% to 1,559 units (SEC Form 4)

      4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

      1/6/25 4:12:14 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on Regeneron Pharma with a new price target

      Cantor Fitzgerald resumed coverage of Regeneron Pharma with a rating of Overweight and set a new price target of $695.00

      4/22/25 7:34:24 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Regeneron Pharma upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Regeneron Pharma from Market Perform to Outperform and set a new price target of $834.00 from $762.00 previously

      2/5/25 7:03:51 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Regeneron Pharma downgraded by UBS with a new price target

      UBS downgraded Regeneron Pharma from Buy to Neutral and set a new price target of $738.00 from $1,130.00 previously

      1/16/25 7:53:14 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REGN
    SEC Filings

    See more
    • SEC Form 13F-HR filed by Regeneron Pharmaceuticals Inc.

      13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

      5/2/25 4:15:32 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Regeneron Pharmaceuticals Inc.

      10-Q - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

      4/29/25 6:51:48 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Regeneron Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

      4/29/25 6:37:44 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REGN
    Leadership Updates

    Live Leadership Updates

    See more

    $REGN
    Financials

    Live finance-specific insights

    See more
    • Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

      TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies, along with its discovery and clinical manufacturing capabilities. 2seventy bio employees who support the acquired programs will join Regeneron Cell Medicines, a newly formed research & development (R&D) unit to advance cell therapies and combination approaches in oncology and immunology. "Regeneron and 2seventy share a relentless commitment to push the boundaries of scie

      1/30/24 7:00:41 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

      NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for

      10/18/23 9:00:00 AM ET
      $AZN
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary

      TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that P. Roy Vagelos, M.D., will retire from his role as Chair of the Company's Board of Directors and will not stand for reelection at the Company's 2023 Annual Meeting of Shareholders. Dr. Vagelos has served as Chair since January 1995 and will complete his current term through the conclusion of the Annual Meeting on June 9, 2023. Effective upon the conclusion of that meeting, the Board plans to appoint Leonard S. Schleifer, M.D., Ph.D., and George D. Yancopoulos, M.D., Ph.D., as Co-Chairs of the Board, in addition to their roles as President and Chief Executive Officer and P

      4/17/23 7:30:00 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

      TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2025 financial and operating results on Tuesday, April 29, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detai

      3/25/25 4:05:00 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025

      TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2024 financial and operating results on Tuesday, February 4, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmati

      1/7/25 4:05:00 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024

      TARRYTOWN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2024 financial and operating results on Thursday, October 31, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email deta

      9/26/24 4:05:00 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases

      24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma COPD data from the landmark Phase 3 trials will highlight Dupixent impact on lung function and health-related quality of life across broad populations of patients with type 2 inflammation Asthma abstracts include late-breaking data on mucus burden and the first presentation of efficacy results from a Phase 2 trial designed to study Dupixent in allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma TARRYTOWN, N.Y., May 01, 2025 (GLOBE NEWSWIRE) --  Regeneron Pharmaceuticals, Inc.

      5/1/25 9:00:00 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease

      Initial real-world data from nearly 40,000 EYLEA HD patients will provide early insights on effectiveness of EYLEA HD in everyday clinical practice New indirect comparisons will evaluate EYLEA HD and faricimab on measures of efficacy, dosing frequency and potential economic benefits in patients with wet age-related macular degeneration and diabetic macular edema TARRYTOWN, N.Y., April 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the upcoming presentation of 27 abstracts, including eight oral presentations on EYLEA HD® (aflibercept) Injection 8 mg in wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retino

      4/28/25 7:00:32 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FUJIFILM Diosynth Biotechnologies and Regeneron Sign a 10-Year U.S. Manufacturing Agreement Valued at Over $3 Billion

      Agreement secures additional U.S. manufacturing capacity to help ensure patient access to medicine FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced a 10-year manufacturing supply agreement, valued at over $3 billion, with Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to provide U.S.-based production of its industry-leading biologic medicines, which treat millions of patients worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422165205/en/FUJIFILM Diosynth Biotechnologies' Holly Springs, N.C. cam

      4/22/25 6:00:00 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • May 20, 2022 - FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

      For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. “As researchers and clinicians have gained knowledge about eosinophilic esophagitis

      5/20/22 3:11:09 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care